Cortexyme, Inc.: directors' dealings · United States · SEC (Form 4)

About Cortexyme, Inc.

Cortexyme, Inc. is a U.S.-based biopharmaceutical company historically traded on the Nasdaq under the ticker CRTX, in the United States. Importantly, the company changed its corporate name to Quince Therapeutics, Inc. effective August 1, 2022, so recent SEC filings and operating disclosures now generally refer to Quince rather than Cortexyme. The company was founded in 2012 in San Francisco and later established its headquarters in South San Francisco, California. ([ir.quincetx.com](https://ir.quincetx.com/news-releases/news-release-details/cortexyme-appoints-dr-philip-low-its-board-directors?utm_source=openai)) Cortexyme originally built its identity around a differentiated scientific thesis: targeting bacterial pathogens, especially P. gingivalis and gingipains, as potential drivers of neurodegeneration and inflammatory disease progression. That concept shaped its early clinical programs, which focused on small-molecule therapeutics intended for Alzheimer’s disease and other degenerative conditions. Over time, however, the company materially reshaped its strategy. After acquiring Novosteo in 2022 and subsequently divesting its legacy protease inhibitor portfolio in 2023, the business shifted toward a precision-therapeutics model centered on rare skeletal diseases and a novel drug-delivery platform. ([ir.quincetx.com](https://ir.quincetx.com/news-releases/news-release-details/cortexyme-announces-agreement-acquire-novosteo?utm_source=openai)) Today, the company is better viewed as a development-stage biotech than as a commercial-stage pharmaceutical company. Its core strategic asset is the AIDE platform, a drug/device combination technology designed to encapsulate a medicine inside the patient’s own red blood cells in order to improve delivery and potentially reduce off-target exposure. The more recent pipeline emphasis is on rare bone disorders, fractures, and adjacent specialty indications. From a competitive standpoint, the company operates in a highly crowded biotech landscape where value creation depends on intellectual property strength, clinical differentiation, regulatory execution, and access to capital. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/qncx-20241231.htm?utm_source=openai)) Geographically, the business remains concentrated in the United States, with its operational and research footprint centered in California. As a Nasdaq-listed issuer, it is subject to the disclosure discipline of the U.S. capital markets, including SEC reporting and insider transaction reporting via Form 4, which is relevant for investors tracking management alignment and ownership changes. ([ir.quincetx.com](https://ir.quincetx.com/news-releases/news-release-details/cortexyme-appoints-dr-philip-low-its-board-directors?utm_source=openai)) The most important recent corporate milestones are the name change to Quince Therapeutics, the acquisition of EryDel in 2023, and the disposal of the legacy Cortexyme portfolio. Taken together, these actions signal a clear strategic pivot away from the original Alzheimer’s-focused thesis toward a broader rare-disease platform. For French-speaking investors, the story is therefore one of a small-cap U.S. biotech undergoing a major transformation: high execution risk, limited near-term visibility, but potentially meaningful upside if the new platform advances successfully through the clinic and toward commercialization. ([ir.quincetx.com](https://ir.quincetx.com/static-files/5414b9e4-2eff-49bf-8fa4-1e56d0787d80?utm_source=openai))